Effects of Intake of Processed Quinoa Seeds on Lipid Profile in Patients with Coronary Heart Disease

Vanessa Oliveira Silva¹, Michele Lima Gregório²,³, Daniel Fernando Villafanha¹, Moacir Fernandes de Godoy¹,³

¹Department of Cardiology and Cardiovascular Surgery – São José do Rio Preto Medical School - FAMERP, São José do Rio Preto, São Paulo, Brazil
²Department of Molecular Biology – São José do Rio Preto Medical School - FAMERP, São José do Rio Preto, São Paulo, Brazil
³Transdisciplinary Nucleus for Chaos and Complexity Studies (NUTECC) - São José do Rio Preto Medical School - FAMERP, São José do Rio Preto, São Paulo, Brazil

Running Title: Intake of Quinoa Seeds on Lipid Profile

Abstract: Background: Quinoa (Chenopodium quinoa Willd) is a gluten-free pseudocereal with high biological value protein, low glycemic carbohydrates, phytoestrols and omega-3 and omega-6 fatty acids. It originated in the Andean region and has been consumed for thousands of years. Our objective was to assess blood cholesterol levels in coronary heart disease (CHD) patients in an outpatient clinic after the intake of processed quinoa seeds. Methods: This is a prospective study with twenty-seven patients, aged between 48 and 70 years (64.0 ± 8.4 yo), who were treated during 120 to 200 days. Blood samples were collected before and after the intake of quinoa seeds to determine the lipid profile of the group. Results: The results showed beneficial effects of the intake of quinoa with a significant reduction in total cholesterol (P=0.0008), triglycerides (P=0.001) and LDLc (P=0.008). Conclusions: The incorporation of quinoa in the eating routine can be considered beneficial in the prevention and control of risk factors for cardiovascular diseases, considered the major causes of death worldwide.

Keywords: Quinoa; Dyslipidemia, Coronary Heart Disease, Biochemical Markers

Introduction
Quinoa (Chenopodium quinoa Willd) is a plant in the Amaranthaceae family, which is extremely tolerant and resistant to climatic stress. It originated in the Andean regions of South America and has been cultivated for over 7,000 years. Quinoa is an excellent source of protein, as it contains mainly lysine, an essential amino acid not usually available in cereals [1]. With an unusual composition and exceptional balance between protein, oil and fat, quinoa is an extraordinary example of functional food, which aims to reduce the risk of various diseases [2].

Therefore, cereals and pseudocereals, such as quinoa, have been extensively investigated for their protective effect in cardiovascular diseases [3]. Some studies have demonstrated the beneficial effects associated with the intake of this crop food on the control of blood pressure, diabetes, obesity and lipid profile. In relation to quinoa, this effect has been attributed to its composition of soluble and insoluble fibers, vitamin E, zinc, iron, magnesium and phytosterols, among other compounds [4].

According to the World Health Organization (WHO), quinoa is considered as unique due to its very high nutritional value. It was rated as the best food of plant origin for human consumption by the United States Academy of Sciences and selected by the National Aeronautics and Space Administration (NASA) to integrate the astronauts' diet into long-duration space flights [5].

With the discovery of its properties, quinoa began to arouse worldwide interest. In America, it can be found from Canada to the south of Chile, with different names, such as “quinoa” or “quinua” in...
Peru, Chile, Argentina and Bolivia, and “suba” [6] in Colombia.

Quinoa stands out as an important source of protein for humans due to its digestibility and essential amino acids composition [7,8].

The ability of the various nutrients found in pseudocereals to reduce the risk of coronary heart disease (CHD) has not been fully clarified, mainly due to their numerous consumption patterns in different populations. However, in the late 1990s, five large prospective cohort studies with 207,000 participants demonstrated an inverse association between intake of grains and cereal fiber and risk of cardiovascular disease [9].

Thus, this study aimed to prospectively assess the effects of the intake of processed quinoa seeds by CHD patients on lipid profile and glycemic control.

Casuistic and Methods
After the studied had been approved by the Research Ethics Committee of the Medical School of São José do Rio Preto (Process Number 136/2009), all 27 participants were informed about the study and confirmed their willingness to participate by signing an Informed Consent Form. All patients had hyperlipidemia and were treated at a University Hospital’s Cardiology Outpatient Clinic. They were also advised on the use and consumption of processed quinoa as food supplement in the first and follow-up sessions.

The following biochemical markers were tested: total cholesterol (TC), low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), very low density lipoprotein cholesterol (VLDLc), triglycerides (TG) and blood glucose before the quinoa intake period (Phase 1), at the end of the intake period (180 days on average, 60-300 days) (Phase 2), and after the end of the intake period (Phase 3).

In this study, the following values were adopted according to the Brazilian Guidelines on Obesity [10]: eutrophic individuals with body mass index (BMI) of 18.5-24.9 kg/m²; overweight individuals with BMI of 25-29.9 kg/m²; and obese individuals with BMI of 30-39.9 kg/m².

The reference values used for CT, LDLc, HDLc, VLDLc, TG and blood glucose were 200 mg/dl, 130 mg/dl, 40 mg/dl, 50 mg/dl, 150 mg/dl and 100 mg/dl, respectively. The results were compared using absolute and relative data with the Chi-Square test, Mann-Whitney test and paired t-test. The significance level was set at P<0.05.

Results
Twenty-seven patients were studied (59% males), where 35% were eutrophic, 45% were overweight and 20% were obese. Regarding blood glucose levels, 62% of patients were normoglycemic and 38% of them were hyperglycemic. All patients were on combined drug therapy for the treatment of heart diseases.

The patients consumed the pseudocereal for approximately 120 to 200 days followed by the laboratory analysis of biochemical markers. After a period of 90 to 200 days without pseudocereal intake, laboratory analysis of these markers was once again conducted in eutrophic, overweight and obese CHD patients.

Tables 1 to 4 show the laboratory analysis of biochemical markers in the total group, in relation to Body Mass Index (BMI), gender and cut-off levels before the intake of the pseudocereal, respectively.
There was a significant reduction in levels of triglycerides, total cholesterol and LDLc between Phase 1 and Phase 2 (P=0.0033; P=0.0022; P=0.0244, respectively); while the same was observed for TC in Phase 3 (P=0.004) (Table 1). Subgroup analysis also demonstrated a significant reduction of blood glucose and triglycerides in obese patients between Phase 1 and Phase 2 (P=0.0497, P=0.0166, respectively), and triglycerides and VLDLc in eutrophic between Phase 1 and Phase 3 (P=0.0424; P=0.0182, respectively) (Table 2).

**Table 2.** Results of the laboratory analysis of biochemical markers in the total group during Phases 1, 2 and 3 of intake of processed quinoa seeds, in relation to BMI

|                  | Phase 1 | Phase 2 | Phase 3 | P- Value |
|------------------|---------|---------|---------|----------|
| **Blood**        |         |         |         |          |
| Eutrophic        | 134±62.0| 96.4±7.4| 106±10.1| 0.1646   |
| Overweight       | 124.9±38.3| 134±58.4| 134.3±65.8| 0.9113 |
| **Glucose**      |         |         |         |          |
| Obese            | 161.5±64.8| 108.9±34.0#| 115.7±37.1| # 0.0497|
| Eutrophic        | 234.8±112.7| 148.1±71.7| 160.7±69.7| 0.1603 |
| **Triglycerides**|         |         |         |          |
| Overweight       | 217.3±168.0| 131.3±67.21| 162.7±121.0| 0.3173 |
| Obese            | 204±88.4| 121.9±23.5#| 157.4±47.4| # 0.0166|
| Eutrophic        | 218.3±41.8| 158.7±60.6| 140.7±60.7##| # 0.0424|
| **Total Chol.**  |         |         |         |          |
| Overweight       | 193.8±57.9| 159.4±48.0| 159.3±35.7| 0.1998 |
| Obese            | 202.7±53.9| 156.5±47.0| 162.4±56.8| 0.1225 |
| Eutrophic        | 58.1±16.0| 56.7±9.9| 63.7±12.2| 0.5754 |
| **HDLc**         |         |         |         |          |
| Overweight       | 53.0±23.8| 48.9±14.8| 40.9±13.9| 0.5189 |
| Obese            | 46.3±11.3| 47.7±12.3| 45.8±20.6| 0.9595 |
| Eutrophic        | 35.8±23.9| 49.7±6.9| 33.2±6.5| 0.7152 |
| **VLDLc**        |         |         |         |          |
| Overweight       | 46.7±33.6| 36.9±19.1| 29.3±13.2| 0.2066 |
| Obese            | 34.8±17.2| 30.3±9.8| 33.2±6.5| 0.7152 |
| Eutrophic        | 154.0±56.6| 105.9±25.2| 93.72±16.8##| # 0.0182|
| **LDLc**         |         |         |         |          |
| Overweight       | 94.6±38.1| 82.1±13.7| 96.5±15.1| 0.3874 |
| Obese            | 116.8±46.1| 94.7±29.2| 113.3±27.5| 0.3371 |

# = comparison between Phase 1 of intake of quinoa vs Phase 2 of intake of quinoa
## = comparison between Phase 1 of intake of quinoa vs Phase 3 of intake of quinoa

In the comparison between the normoglycemic and hyperglycemic subgroups, the effect of quinoa was significant only in total cholesterol among normoglycemic patients (P=0.0019; P=0.0023) and HDLc among hyperglycemic patients (P=0.001; P=0.0018), maintaining a significant difference in Phase 3 (Table 3).

**Table 3.** Results of the laboratory analysis of biochemical markers in the total group during Phases 1, 2 and 3 of intake of processed quinoa seeds, according to blood glucose level

|                  | Phase 1 | Phase 2 | Phase 3 | P- Value |
|------------------|---------|---------|---------|----------|
| **Triglycerides**|         |         |         |          |
| Normogl.         | 223.9±35.4| 138.4±60.3| 181.3±28.9| 0.11 |
| Hipergl.         | 215.4±39.5| 139±62.6| 179±35.5| 0.2673 |
| **Total Chol.**  |         |         |         |          |
| Normogl.         | 233.4±43.1| 149.4±35.0#| 151.1±36.5##| #0.0019;##0.0023|
| Hipergl.         | 180.8±34.8| 160.2±57.2| 168±47.2| 0.6224 |
| **LDLc**         |         |         |         |          |
| Normogl.         | 133.1±46.0| 102.6±10.1| 100.8±13.8| 0.084 |
| Hipergl.         | 105±50.1| 88.6±35.3| 108.8±30.7| 0.4945 |
| **HDLc**         |         |         |         |          |
| Normogl.         | 58.9±13.1| 55.2±10.5| 67.1±16.3| 0.2693 |
| Hipergl.         | 45.7±10.3| 47.9±11.1#| 54.8±28.8##| #0.001;##0.0018|

# = comparison between Phase 1 of intake of quinoa vs Phase 2 of intake of quinoa
## = comparison between Phase 1 of intake of quinoa vs Phase 3 of intake of quinoa

Regarding gender, the best result was the reduction of triglycerides and total cholesterol (P=0.0037; P=0.0037) among men, and LDLc (P=0.0258; P=0.0314) and HDLc (P=0.0004) among women (Table 4).
In a recent study [12], 22 patients (18-45 years), who consumed quinoa cereal bars during 30 days, showed a significant reduction in total cholesterol levels among women, but not among men.

Hirose et al. [13] analyzed the crude extracts from quinoa seeds cultivated in Japan, which showed higher antioxidant effects than those from South America.

Variations in antioxidant activity of quinoa genotypes were already expected, since several factors (genetic and agro-technical processes and environmental conditions) may influence the presence of phenolic compounds [14]. Also, the agronomic, physical, nutritional and antioxidant properties of six different genotypes of quinoa cultivated in three different geographic zones of Chile were analyzed. Such contrasting features might be associated with sow-to-harvest period and sensitivity to higher temperatures. In contrast, the crop harvested in the southern region stood out in terms of total dietary fiber, i.e., 12.08g of fiber per 100g of the analyzed seeds [15].

Another study assigned 13 patients with type 2 diabetes mellitus to follow two types of diet for six weeks: a diet containing moderate amounts of fiber (total, 24g, 8g soluble fiber and 16g of insoluble fiber), as recommended by the American Diabetes Association (ADA), and a high-fiber diet (total, 50g, 25g of soluble fiber and 25g of insoluble fiber). Both diets were prepared in a research kitchen and had the same macronutrient and energy content. The effects of both diets on glycemic control and plasma lipid concentrations were compared and a reduction on plasma lipid concentrations, triglyceride levels and LDLc concentrations could be observed. In conclusion, a high intake of dietary fiber, especially of the soluble type, above the level recommended by the ADA promotes the following benefits: improving glycemic control, decreasing hyperinsulinemia and reduced plasma lipid concentrations in patients with type 2 diabetes mellitus [16].

As a high-protein food, quinoa was added to dark chocolate bars in another study. The product showed increase in essential amino acids and was approved by 92% of the group of testers [17]. A rich-content protein beverage from mixing quinoa and lupine was also developed for children aged between 2 and 5 years with nutritional deficiencies. The beverage was stored for 90 days and subsequently tested. The results showed that the protein content was 1.36% [18].

Karlström et al. [19] studied the metabolic effects of an increased dietary content of cereal fiber in 14 type 2 diabetic individuals. These individuals received a diet containing 18.9g fiber/day during two consecutive periods of 3 weeks, and a significant reduction in mean blood glucose level could be observed.

Nsimba et al. [20] evaluated the antioxidant potential of extracts from quinoa and amaranth and found high levels of phenolic and non-phenolic compounds, which could justify such protective effect.

Quinoa stands out as an important source of protein for humans because of its digestibility and balanced essential amino acids composition. In experiments with rats, the analysis of protein efficiency coefficient, true digestibility and nitrogen balance showed similarity between the efficiency of the

---

Table 4. Results of the laboratory analysis of biochemical markers in the total group during Phases 1, 2 and 3 of intake of processed quinoa seeds, according to gender (Males=M; Females=F).

|                | Phase 1         | Phase 2         | Phase 3         | P-Value |
|----------------|-----------------|-----------------|-----------------|---------|
| Triglycerides  |                 |                 |                 |         |
| M              | 217.9±124.5     | 127.5±1.2       | 147.3±49.1      | # 0.0094|
| F              | 215.4±131.1     | 139±62.6        | 179±117.8       | 0.267   |
| Total Chol.    |                 |                 |                 |         |
| M              | 184.5±47.9      | 135.3±27.11     | 135.3±4.6       | # 0.0037;## 0.0037 |
| F              | 231±45.6        | 191.3±55.9      | 185.1±44.7      | 0.0746  |
| LDLc           |                 |                 |                 |         |
| M              | 97.9±36.1       | 85.6±20.0       | 100±21.4        | 0.2820  |
| F              | 147.8±54.1      | 103.5±27.2 #    | 104.9±23.6 #    | # 0.0258;# 0.0314 |
| HDLc           |                 |                 |                 |         |
| M              | 61.8±17.9       | 54.7±13.8       | 59.4±20.36      | 0.5594  |
| F              | 151.1±45.4      | 153.1±25.8      | 155.5±21        | # 0.0004 |

# = comparison between Phase 1 of intake of quinoa vs Phase 2 of intake of quinoa
## = comparison between Phase 1 of intake of quinoa vs Phase 3 of intake of quinoa
protein in quinoa and milk protein [7]. This result could also be observed in a study with humans.

Jenkins et al. [21] assessed the effect of food products (breakfast cereals, breads, frozen pasta, cakes and biscuits) supplemented with Psyllium (7.2g) and Beta-glucans (7.2, Oats), in 37 men and 31 postmenopausal and hypercholesterolemic women in a one-month period and found significant reductions in serum lipid concentrations, confirming the beneficial effect of dietary fiber intake.

A curious finding of the study is that quinoa is consumed in the Andean region, among other forms, as a fermented alcoholic beverage called “Chicha”. The technique is over 1,000 years old and the preparation of the seeds begins with the germination. At this stage, the starch is broken and the substrate is made available for bacterial fermentation. The major natural bacteria found in quinoa are of the genus Lactobacillus (L. plantarum, L. fermentum and L. paralimentarius), which carry out lactic fermentation and have organic acids as the main end product of metabolism. The organic acids produced by the fermentation may delay gastric emptying [22].

Gewehr [23] prepared breads by replacing wheat flour with quinoa flakes. The composition was analyzed according to contents of amino acids, fibers, tocopherols and minerals, showing higher protein content, total fiber, and tocopherol. The increase in tocopherols in bread with 20% of quinoa improved the lipid profile of blood and liver fat of experimental animals, compared to white bread. Vannucchi & Jordão [24] report that tocopherols have antioxidant activities as they are incorporated into the lipid portion of cell membranes and play the role of protecting this structure from toxic compounds, radiation and free radicals, in addition to protecting cholesterol from oxidative damage.

All patients showed coronary heart diseases and hyperlipidemia; however, other risk factors may also be associated with cardiovascular complications. Thus, it could be observed that 55% of the patients had high blood pressure, 85% smoked regularly, 26% showed moderate alcohol consumption, and 63% of the patients had a sedentary lifestyle.

Dietary supplements have been referred to as adjuvants in an attempt to reduce the risk for coronary artery disease. In this study, the intake of processed quinoa aimed to reduce or control hyperlipidemia. It was found that 95% of the patients approved the taste of the pseudocereal and agreed to change their eating habits and include vegetables, fruits and legumes in their daily meals.

Several studies have demonstrated that the dietary intake of pseudocereals provides beneficial effects in the studied populations [25]. Further studies show that fiber intake reduces the risk of cardiovascular diseases, hyperlipidemia, obesity and diabetes [4].

According to Berti et al. [26] the intake of quinoa, including soluble and insoluble fiber, may be considered nutraceutical as it reduces the levels of blood glucose, triglyceride and cholesterol. Our results in the present study demonstrate that quinoa can be used to reduce these types of hyperlipidemia.

Quinoa contains high amounts of vitamin E, zinc, manganese, phytosterols, as well as substances with hypocholesterolemic effects [27]. Antioxidants, polyphenols and flavonoids can also be found in processed quinoa. These substances are associated with the reduction of plasma lipids, blood glucose levels and cardiovascular diseases [28]. Matsuo [29] demonstrated that quinoa may have beneficial effects on reducing the production of antioxidant enzymes, in addition to decreasing LDLc oxidation and the risk of cardiovascular diseases.

Ando et al. [30] and Konish et al. [31] analyzed the minerals content of milled quinoa (sample of 100 g), and found higher levels of calcium (55.1 to 91.8 mg), phosphorus (360.2 to 411.0 mg), potassium (639.3 to 732.0 mg), magnesium (415.2 to 502.0 mg), iron (9.2 to 15.0 mg) and zinc (0.8 to 4.0 mg). Some studies have shown that quinoa seeds contain significantly higher amounts of these minerals when compared to most cereals commonly consumed in Brazil, such as wheat, maize, rice and oats [32-35]. Quinoa has a high concentration of lysine, unlike most pseudocereals [36,37].

The present study demonstrated that quinoa positively influences the reduction of lipidemic alterations and glycemic control, thus contributing to the reduction of risk for the development of cardiovascular diseases.

Conclusions
The use of processed quinoa seeds as food supplement for hyperlipemic patients allowed a significant reduction in the levels of blood glucose, total cholesterol, LDLC and triglycerides in specific subgroups and in specific phases, namely:
1. Significant reduction in levels of triglycerides, total cholesterol and LDLC between Phase 1 and
The findings suggest that quinoa may be considered useful to reduce risk factors for cardiovascular disease. Long-term event studies should be conducted in order to confirm this hypothesis.

Acknowledgments
We thank all participants and their families for their important contribution to this research.

Conflict of Interest Statement
The authors declare no conflict of interest.

Funding sources
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

References
1. De Ron AM, Sparvoli F, Pueyo JJ, Bazile D: Editorial: Protein Crops: Food and Feed for the Future. Front Plant Sci. 2017;8:105.
2. James LE A: Quinoa (Chenopodium quinoa Willd.): composition, chemistry, nutritional and functional properties. Adv Food Nutr Res 2009;58:1-31.
3. Farinazzi-Machado FMV, Barbalho SM, Oshiwi M, Goulart R, Pessan OJ: Use of cereal bars with quinoa (Chenopodium quinoa W.) to reduce risk factors related to cardiovascular diseases. Ciência Tecnol Alimentos. 2012;32:239–44.
4. Devalaraja S, Jain S, Yada VH: Exotic Fruits as Therapeutic Complements for Diabetes, Obesity and Metabolic Syndrome. Food Res Int. 2011;44:1856-65.
5. Stocco CQF, Nichelle F: Propriedades da Quinua Real. [S.I., s/n.], 2008. Disponível em: http://www.nutricoeasaudenav.com.br/imagens/artigos/64.pdf Acesso em: 12 dez 2013.
6. Ruiz WA: Estudo cromatográfico das saponinas da quinoa (Chenopodium quinoa Willd. variedade kancolla). 1979. 135 t. Dissertação (Mestrado) – Faculdade de engenharia de alimentos e agricola, Universidade Estadual de Campinas, Campinas, 1979.
7. Ranhotra GS, Gelroth JA, Glaser BK, Lorenz KJ, Johnson DL: Composition and protein nutritional quality of quinoa. Cereal Chem. 1993;70:303-05.
8. Mújica A: Neglected crops: 1.492 from a different perspective; in Hernández-Bermejo JE, Léon J (eds): FAO Plant production and protection series, n. 26. Rome: FAO, 1994.
9. Willet WC: The dietary pyramid: does the foundation need repair? Am. L. Printed in USA. Am Soc Clin Nutr. 1998;68:218-19.
10. Diretrizes Brasileiras de Obesidade - ABESO – Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. p p.16, 4ª Ed., São Paulo – SP, 2016.
11. Paiko P, Zagrodski P, Bartoň H, Chlopicka J, Gorinstein S: Effect of quinoa seeds (Chenopodium quinoa) in diet on some biochemical parameters and essential elements in blood of high fructose-fed rats. Plant Foods Hum Nutr. 2010;65:333-38.
12. Farinazzi-Machado F, Barbalo SM, Oshiwi M, Goulart R, Pessan OJ: Use of cereal bars with quinoa (Chenopodium quinoa W.) to reduce risk factors related to cardiovascular diseases. Ciência Tecnol Alimentos. 2012;32:239–44.
13. Hirose Y, Fujita T, Ishii T, Ueno N: Antioxidative properties and flavonoid composition of Chenopodium quinoa seeds cultivated in Japan. J Food Chem. 2010;119:1300-06.
14. Álvarez-Jubete L, et al: Composição de polifenóis e atividade antioxidante nitro de amaranto, quinoa, trigo e trigo em função da brotação e panificação. Food Chem. 2010;119:770-78.
15. Miranda M, Gálvez A, Martínez E, López J, Rodríguez M, Henriquez K, Fuentes F: Genetic diversity and comparison of physicochemical and nutritional characteristics of six quinoa (Chenopodium quinoa Willd.) genotypes cultivated in Chile. Ciência Tecnol Alimentos. 2012;32:835-43.
16. Chandalia M, Garg A, Litjohann D, von Bergmann K, Grundy SM, Brinkley LJ: Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med. 2000;342:1392–398.
17. Schumaker A, Brandelli A, Macedo F, Pieta L, Klug T, Jorg E: Chemical and sensory evaluation of dark chocolate with addition of quinoa (Chenopodium quinoa Willd.). J Food Sci Technol. 2010;47:202–06.
18. Mesquita C, Barrientos A, Valdivia R, Palacios R, Zavala A: Development of a high content protein beverage from Chilean mesquite, lupine and quinoa for the diet of preschoolers. Nutr Hosp. 2012;27:232–43.
19. Karlström B, Vessby B, Asp NG, Boberg M, Gustafsson IB, Lethl H, Werner I: Effects of an increased content of cereal fibre in the diet of type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1984;26:272-7.
20. Nismba RY, Kikusaki H, Konish Y: Antioxidant activity of various extracts and fractions of Chenopodium quinoa and Amaranthus spp. seeds. Food Chem. 2008;106:760–66.
21. Jenkins DJA, Kendall CWC, Vuksan V, Widdgen E, Parker T, Faulchner D, et al: Soluble fiber intake at a dose approved by the US Food and Drug Administration for 55 a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr. 2002;75:834-39.
22. Otman ME, Nilsson M, Liljeberg Elmhård HGM, Molin G, Björck IME: On the effect of lactic acid on blood glucose and insulin responses to cereal product: mechanist studies in health subjects and in vitro. J Cereal Sci. 2002;36:339-46.
23. Gewehr FM: Desenvolvimento de pães de forma com adição de quinoa.
Effects of Intake of Processed Quinoa Seeds on Lipid Profile in Patients with Coronary Heart Disease

http://www.lume.ufg.br/bitstream/handle/10183/24809/000749081.pdf?sequence=1. Captado em 15 de março de 2014.

24. Vannucchi H, Jordão A: Radicais livres, antioxidantes dieta: a importância das frutas e verduras, in Angelis RC: Importância de alimentos vegetais na proteção da saúde. I ed. São Paulo, Atheneu, 2001. cap. 35, p. 193-201.

25. Santos RD: III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivo Brasileiro Cardiologia. 2001; 77(3):1-48. /// Brasil. Ministério da Saúde. Conselho Brasileiro sobre Diabetes: diagnóstico e classificação do Diabetes Mellitus e tratamento do Diabetes Mellitus tipo 2. Brasília; 2000.

26. Berti C, Riso P, Brusamolino A, Porrini M: Effect on appetite control of minor cereal and pseudocereal products. B J Nutr. 2005;94:850-58.

27. Kwon DY, Kim YS, Hong SM, Park S: Long-term consumption of saponins derived from Platycodi radix (22 years old) enhances hepatic insulin sensitivity and glucose-stimulated insulin secretion in 90 % pancreatectomized diabetic rats fed a high-fat diet. B J Nutr. 2008;25:1-9.

28. Ascheri J, Nascimento R, Spehar C: Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperblood glucose and hypertension of commonly used medicinal plants, herbs and spices in Latin America. Bioreour Technol. 2010;102:4676-89.

29. Matsuo M: In vivo antioxidant activity of methanol extract from quinoa fermented with Rhizopus oligosporus. J Nutr Sci Vitaminol. (Tokyo) 2005;51:449-52.

30. Ando H, Chen Y, Tang H, Shimizu M, Watanabe K, Mitsunaga T: Food components in fractions of quinoa seed. Food Sci Technol Res 2002;8:80-4.

31. Konish Y, Hirano S, Tsuboi H, Wada M: Distribution of minerals in quinoa (Chenopodium quinoa Willd.) seeds. Biosci Biotechnol Biochem. 2004;68: 231-34.

32. Borges J, Ascheri D, Nascimento R, Freitas A: Propriedades de cozimento e caracterização físico química de macarrão pré-cozido à base de farinha integral de quinoa (Chenopodium quinoa Willd.) e de farinha de arroz (Oryza Sativa, L) polido por extrusão termoplástica. Boletim CEPPA 21 (2): 303-322, 2003.

33. Bhargava A, Shukla S, Ohri D: Chenopodium quinoa- An Indian perspective. Ind Crops Prod. 2006;23:73-87.

34. Vilche C, Gely M, Santalla E: Physical properties of quinoa seeds. Biosyst Eng. 2003;86: 59-65.

35. Abagoch LE, Romero N, Tapia CR, Silva J, Rivera M: Study of Some Physicochemical and Functional Properties of Quinoa (Chenopodium quinoa Willd) Protein Isolates. J Agric Food Chem. 2008;56:4745-750.